Venus Medtech (Hangzhou) Inc. Stock price

Equities

2500

CNE100003PJ8

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 03:08:30 2023-11-22 am EST 5-day change 1st Jan Change
5.62 HKD -0.71% Intraday chart for Venus Medtech (Hangzhou) Inc. -.--% -.--%

Financials

Sales 2023 * 566M 78.69M 615M Sales 2024 * 809M 112M 880M Capitalization 2.26B 314M 2.46B
Net income 2023 * -570M -79.26M -620M Net income 2024 * -289M -40.19M -314M EV / Sales 2023 * 3.27 x
Net cash position 2023 * 410M 56.96M 445M Net Debt 2024 * 125M 17.4M 136M EV / Sales 2024 * 2.95 x
P/E ratio 2023 *
-3.99 x
P/E ratio 2024 *
-7.92 x
Employees 1,006
Yield 2023 *
-
Yield 2024 *
-
Free-Float 73.87%
More Fundamentals * Assessed data
Dynamic Chart
Venus Medtech Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away CI
Venus Medtech Names Former 3SBio Finance Chief as CFO MT
Venus Medtech Inc. Appoints Fei Wang as the Chief Financial Officer CI
Venus Medtech Gets Trading Resumption Guidance MT
Venus Medtech Inc. Approves Mr. Liqiao Ma as an Executive Director CI
Venus Medtech Concludes Probe into Funds Loaned to Ex-Directors; Declares Remedial Action MT
Venus Medtech to Market Valgen Medtech's Heart Valve Repair System Across China MT
Venus Medtech Inc. Announces Executive Changes CI
Venus Medtech Names Joint CEO MT
Venus Medtech Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023 CI
Venus Medtech's H1 Attributable Loss Widens MT
Venus Medtech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
US FDA Grants Clinical Trial Approval to Venus Medtech's Pulmonary Valve Replacement MT
Venus Medtech Inc. Announces it's Self-Developed Transcatheter Pulmonary Valve Replacement System VenusP-Valve Received the Approval of IDE (Investigational Device Exemption) Application from the US Food and Drug Administration CI
Venus Medtech’s General Manager Boosts Shareholding to 12% MT
More news
1 day-0.71%
3 months-0.71%
6 months+2.55%
More quotes
1 year
3.74
Extreme 3.74
14.48
3 years
3.74
Extreme 3.74
79.70
5 years
3.74
Extreme 3.74
97.00
10 years
3.74
Extreme 3.74
97.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 16-11-30
Director of Finance/CFO 47 23-01-03
Director/Board Member 47 17-10-31
Members of the board TitleAgeSince
Chief Executive Officer 50 16-11-30
Chairman 69 18-11-25
Director/Board Member 41 18-11-25
More insiders
Venus MedTech (HangZhou) Inc. is a China-based company engaged in the research, development, manufacture and sales of minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.157 CNY
Average target price
8.125 CNY
Spread / Average Target
+57.57%
Consensus
  1. Stock
  2. Equities
  3. Stock Venus Medtech (Hangzhou) Inc. - Hong Kong S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer